Chimerix, Inc. (CMRX)
CMRX moved a median of 0.00% 30 minutes after news, and +0.12% by the close. How CMRX actually reacts to news — the realized, point-in-time move the market made, measured across 187 labeled events over the last three years with zero look-ahead.
CMRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 51% | 146 |
| 30-min | 0.00% | 48% | 151 |
| 60-min | 0.00% | 48% | 151 |
| to close | +0.12% | 53% | 152 |
| Middle 50% of CMRX reactions | -0.74% to +0.33% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 187 |
Half of all Chimerix, Inc. news events land between -0.74% and +0.33% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CMRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | +0.18% | 64% | +0.41% |
| Rating reiterations | 22 | -0.10% | 41% | +0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CMRX ranks against every other measured name →
That’s how CMRX usually reacts — get an email when it moves on news →Email me when CMRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CMRX's baseline. Nothing else.
Recent CMRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G CHIMERIX INC | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT CHIMERIX INC | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K CHIMERIX INC For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM CHIMERIX INC | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS CHIMERIX INC | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-K/A CHIMERIX INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.06% | -0.12% | |
| Chimerix Reports Fourth Quarter and Year End 2024 Financial Results | Press release | GlobeNewswire | +0.00% | +0.12% | |
| Form 10-K CHIMERIX INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.12% | |
| Form 8-K CHIMERIX INC For: Mar 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.12% | |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.12% | +0.47% | |
| CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders | Press release | GlobeNewswire | +0.06% | +0.12% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC) | Press release | GlobeNewswire | +0.12% | +0.41% | |
| CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.06% | +0.71% | |
| Form 8-K CHIMERIX INC For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +0.71% | |
| Form 8-K/A CHIMERIX INC For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +0.12% | |
| Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio | Press release | GlobeNewswire | +0.06% | +0.71% | |
| Form 8-K CHIMERIX INC For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -2.52% | |
| Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma | Press release | GlobeNewswire | -1.19% | -3.98% | |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.99% | +1.40% | |
| Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium | Press release | GlobeNewswire | -0.49% | -0.48% | |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.01% | +3.33% | |
| Chimerix to Speak Today at The White House Cancer Moonshot Forum | Press release | GlobeNewswire | -1.06% | +3.44% | |
| Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma | Press release | GlobeNewswire | -4.11% | -5.75% | |
| Form 8-K CHIMERIX INC For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | -4.11% | -5.75% | |
| Form 8-K CHIMERIX INC For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +3.69% | +27.19% | |
| Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End | Press release | GlobeNewswire | +3.69% | +27.19% | |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.01% | +2.98% | |
| Form 8-K CHIMERIX INC For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -3.38% | |
| Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | Press release | GlobeNewswire | +2.06% | +7.22% | |
| Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update | Press release | GlobeNewswire | -0.99% | -4.55% | |
| Form 10-Q CHIMERIX INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.99% | -4.55% | |
| Form 8-K CHIMERIX INC For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -4.55% | |
| Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 | Press release | GlobeNewswire | -0.46% | +1.59% | |
| Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.11% | +0.00% | |
| Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference | Press release | GlobeNewswire | -0.73% | -8.46% | |
| Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.73% | -8.46% | |
| Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +0.70% | -4.22% | |
| Form 10-Q CHIMERIX INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.70% | -4.22% | |
| Form 8-K CHIMERIX INC For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.70% | -4.22% | |
| Form S-8 CHIMERIX INC | SEC filing · Form S-8 | SEC EDGAR | +2.19% | +8.66% | |
| Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024 | Press release | GlobeNewswire | +1.45% | -1.60% | |
| Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.08% | -1.51% | |
| Form 8-K CHIMERIX INC For: Jun 27 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 8-K CHIMERIX INC For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | -0.97% | +2.01% | |
| Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.99% | +5.81% | |
| Form EFFECT CHIMERIX INC | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +5.26% | |
| Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update | Press release | GlobeNewswire | -5.94% | +0.13% | |
| Form 10-Q CHIMERIX INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.94% | +0.13% | |
| Form 8-K CHIMERIX INC For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -5.94% | +0.13% | |
| Form DEF 14A CHIMERIX INC For: Apr 26 | SEC filing · Form DEF | SEC EDGAR | +0.72% | -0.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CMRX section they belong to.
Where else CMRX is measured.
CMRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| KHIRON LIFE SCIENCES CORP (KHRNF) | 189 | +0.07% | 50% |
| NEON THERAPEUTICS (NTGN) | 189 | -0.69% | 38% |
| BioSig Technologies, Inc. (BSGM) | 186 | +0.64% | 55% |
| SIGA Technologies Inc. (SIGA) | 186 | -0.10% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Chimerix, Inc.'s median reaction calculated?
Every labeled CMRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 187 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CMRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CMRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.